IceCure Medical Ltd. (ICCM) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for standing by. Good morning, and thank you for standing by. Currently, all participants are in a listen-only mode. After management's discussion, there will be a question-and-answer session. Please be advised that today's conference call is being recorded. I would now like to hand over the call to Michael Poliview. Please go ahead. Thank you, Yanni, and welcome to IceCure Medical's conference call to review the financial results as of and for the six months ended June 30, 2025, and provide an update on recent operational highlights. You may refer to the earnings press release that we issued earlier this morning. Participating on today's call are ice care medical CEO and also mayor in the company CFO and CEO Ronan Zimmerman. Before we begin, I'll not take a moment to read a statement about photo statements. This call in the question and answer session that follows it contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as expects, anticipates, intends, plans, believes, speaks, estimates, and similar expressions or variations of such words are intended to identify forward-looking statements. For example, we are using forward-looking statements in this presentation when we discuss But the company is optimistic that regulatory approval for ProSense will be granted before year-end 2025. The expectation that there is more clinical data forthcoming from independent researchers. The belief that the recent rights offering is a strong indicator in the vote of confidence from the company shareholders and that it will provide a sufficient cash runway for the anticipated FDA marketing authorization decision. The ex...